BKI-1369
CAS : 1951431-22-3
Ref. 3D-BDD43122
| 1mg | À demander | ||
| 5mg | À demander | ||
| 10mg | À demander | ||
| 25mg | À demander | ||
| 50mg | À demander |
Informations sur le produit
BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied for use in the treatment of infectious diseases. It has been shown to have a broad spectrum of activity against bacteria and protozoa, including multidrug-resistant strains. BKI-1369 has been successful in animal studies with peroxides, which are toxic compounds generated by some bacteria. It has been shown to be active against c. parvum and intestinal-dwelling bacteria such as E. coli and Enterococcus faecalis. Clinical trials have demonstrated that BKI-1369 is effective in treating mucosal lesions caused by Chlamydia pneumoniae, Mycoplasma hominis, or C. parvum in humans or animals. This drug targets the enzyme thymidine phosphorylase, which is essential for bacterial growth and replication.
Propriétés chimiques
Question d’ordre technique sur : 3D-BDD43122 BKI-1369
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
